Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

FTSE 100 posts fourth straight week of gains while Reckitt, Shire fall

Published 20/04/2018, 17:07
Updated 20/04/2018, 17:07
© Reuters. A man walks past the London Stock Exchange in the City of London

© Reuters. A man walks past the London Stock Exchange in the City of London

By Helen Reid

LONDON (Reuters) - Weaker sterling helped Britain's FTSE 100 (FTSE) outperform European markets on Friday, while consumer giant Reckitt Benckiser tumbled after disappointing results and Shire declined as Allergan pulled out of the running to acquire the company.

The leading UK stock index closed up 0.54 percent at 7368.17 points, posting a fourth straight week of gains with a 1.4 percent rise, its longest winning streak since mid-January.

Sterling fell after Bank of England Governor Mark Carney dampened widespread expectations for an interest rate hike in May.

The decline supported export-oriented large-cap stocks, which dominate the FTSE 100. But sterling is still up four percent this year so far, making the multinationals relatively less attractive to investors.

Underneath the index level, earnings continued to set the tone for trading.

Reckitt Benckiser (L:RB) shares fell 2.8 percent after the maker of Dettol products reported that sales growth had missed expectations, including sluggish results at its Scholl footcare brand.

"Scholl continues to be a major drag on growth, suggesting that RB's issues in this brand are not confined to a 'one-off' product failure but are instead more widespread, and raises questions on whether RB's investment into gadgets is the right innovation strategy for the company," said UBS analysts.

Shire (L:SHP) shares fell back 3.9 percent after Allergan (N:AGN) ruled out a bid for the company, whose shares have been on a rollercoaster ride as Takeda Pharmaceuticals and other bidders jostle to acquire it.

"It's disappointing there are not two companies after it, but on the other hand it should spur Shire management to be more proactive and come up with a decent defence and outline their longer term prospects," said Paul Mumford, fund manager at Cavendish Asset Management.

The drugmaker's shares had spiked to a more than eight-month high on Thursday after Reuters reported Shire rejected Takeda Pharmaceuticals' $63 billion offer for the firm.

CRH (I:CRH) shares gained 4.1 percent after the Irish building materials company's CEO told the Irish Times the group was reviewing the possibility of a share buyback and a potential listing of part of its U.S. business.

"We believe the odds of [a U.S. spin-off] remain low given the CEO's comments around synergies from having a globally integrated group," said analysts at Davy Research.

Tobacco companies British American Tobacco (L:BATS) and Imperial Brands (L:IMB) recovered slightly from Thursday's slump when weak results from Philip Morris in the U.S. dented cigarette makers. The stocks were up 1.4 percent and 2 percent respectively.

They also benefited from the weaker sterling, as they make most of their earnings in foreign markets.

In the FTSE 250 (FTMC), pub operator Greene King (L:GNK) was the stand-out faller, down 3.1 percent after Berenberg cut its price target on the stock, reiterating a "sell" rating.

© Reuters. A man walks past the London Stock Exchange in the City of London

"In our view, the company is having to pedal increasingly hard to maintain current levels of sales across its estate," said analysts at the German broker.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.